Non-alcoholic fatty liver disease: an emerging pathological spectrum

  title={Non-alcoholic fatty liver disease: an emerging pathological spectrum},
  author={Elie Serge Zafrani},
  journal={Virchows Archiv},
The spectrum of pathological lesions observed in non-alcoholic fatty liver disease (NAFLD) is wide and strongly resembles that of alcohol-induced liver disease. It ranges from fatty liver to steatohepatitis, progressive fibrosis and cirrhosis. Hepatocellular carcinoma is a possible complication of NAFLD, but whether it is related to frequently associated metabolic disorders (e.g., overweight, diabetes) or to underlying cirrhosis is unclear. This disease is the result of a multi-factorial… 

Nonalcoholic fatty liver disease . A pathological spectrum -

The hepatic lesions probably reflect the pathophysiological mechanisms leading to NAFLD and may also be drug induced and secondary to intestinal bypass or resection, to total parenteral nutrition or to lipodystrophy.

Nonalcoholic fatty liver disease: pathogenesis and histological findings, with emphasis on mitochondrial alterations.

Nonalcoholic fatty liver disease is a complex multifactorial process in which the genetic environment has considerable importance, since it is still unknown why some patients have only steatosis while others develop steatohepatitis, cirrhosis or hepatocellular carcinoma.

Nonalcoholic Fatty Liver Disease: Review

There is a lack of large, randomized, placebo-controlled trials of adequate treatment duration, with baseline stratification according to histologic severity, and in the absence of proven therapies, treatment is directed toward weight loss and comorbidity management.

PPARa in the Pathogenesis of Fatty liver Disease

  • Medicine
  • 2005
atty liver disease (FLD), which is emerging as the most common liver disease in clinical practice, is F etiologically diverse and encompasses a morphological spectrum consisting of hepatic steatosis

Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?

The cases presented here suggest that NAFLD may predispose patients to HCC in the absence of cirrhosis, and further studies are needed to confirm this potentially important observation.

Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation.

  • J. ReddyM. Rao
  • Medicine
    American journal of physiology. Gastrointestinal and liver physiology
  • 2006
The indistinguishable spectrum of histological features of both AFLD and NAFLD suggests a possible convergence of pathogenetic mechanisms at some critical juncture that enables the progression of steatohepatitis toward cirrhosis and liver cancer.

Potential Biomarkers for “Fatty Liver” (Hepatic Steatosis) and Hepatocellular Carcinoma (HCC) and an explanation of their pathogenesis

Several biomarker candidates in the phosphatidylcholine fraction for which a 36:1 PCh could accounted as a clear biomarker for HCC are found in this C57bl6 mouse model, highlighting new biochemical insights on molecular mechanisms underlying liver cancer disease.

Review article: is non‐alcoholic fatty liver disease a spectrum, or are steatosis and non‐alcoholic steatohepatitis distinct conditions?

  • Y. Yılmaz
  • Medicine
    Alimentary pharmacology & therapeutics
  • 2012
Non‐alcoholic fatty liver disease (NAFLD) is currently conceptualised as a clinical spectrum that results from a ‘multiple‐hit’ process which begins with simple steatosis and subsequently renders the

[Non-alcoholic fatty liver disease].

Hepatic steatosis and fibrosis in chronic hepatitis C in Taiwan.

Hepatic steatosis was associated with being overweight, hepatic fibrosis, and triglyceride level in chronic hepatitis C, and according to multivariate analysis, BMI is the strongest risk factor associated with hepatic Steatosis.



Nonalcoholic fatty liver disease.

  • P. Angulo
  • Medicine, Biology
    Revista de gastroenterologia de Mexico
  • 2005
Nonalcoholic fatty liver disease is associated with an increased risk of all-cause death, probably because of complications of insulin resistance such as vascular disease, as well as due to cirrhosis and hepatocellular carcinoma, which occurs in a minority of patients.

Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors

Statohepatitis (fatty liver hepatitis), histologically identical to alcoholic disease, occurs in some obese patients after jejunoileal bypass, and incidence of steatosis and steatohePatitis correlated with the degree of obesity.

Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Moderate alcohol consumption seems to reduce the risk of NAFLD in the severely obese, possibly by reducing insulin resistance and systemic hypertension, features of the metabolic syndrome.

AGA technical review on nonalcoholic fatty liver disease.

In this review, the existing literature regarding the nomenclature, clinical and histologic spectrum, natural history, diagnosis, and management of nonalcoholic fatty liver disease are discussed.

Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

Features suggestive of NASH are more frequently observed in HCC arising in patients with CC than in age- and sex-matched HCC patients of well-defined viral or alcoholic etiology.

The natural history of nonalcoholic fatty liver: A follow‐up study

In the absence of preexisting fibrosis or steatohepatitis, fatty liver of nonalcohol‐induced origin is an extremely benign condition.

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

The presence of multiple metabolic disorders is associated with a potentially progressive, severe liver disease and the increasing prevalence of obesity, coupled with diabetes, dyslipidemia, hypertension, and ultimately the metabolic syndrome puts a very large population at risk of forthcoming liver failure in the next decades.

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

Steatosis is an important cofactor in increasing liver necroinflammatory activity and in accelerating fibrosis in chronic hepatitis C and Visceral obesity and genotype 3a play a role in the development of steatosis.

Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

The entire histologic spectrum of NAFLD can be seen in individuals with normal ALT values, and the Histologic spectrum in these individuals is not significantly different from those with elevated ALT levels, which means a lownormal ALT value does not guarantee freedom from underlying steatohepatitis with advanced fibrosis.